This interactive case-based webinar worth 1.5 CME, will answer your common questions and challenges related to HER2 and ER/PgR testing. Two of the ASCO/CAP Guideline authors will facilitate a tumor board-like experience where participants weigh-in on real patient cases. This is a unique opportunity to come together and learn from the experts and other pathologists doing breast predictive factors testing.

As a result of participating in this education activity, you will be able to:
 1. Accurately interpret HER2 tests as positive, negative or equivocal
     according to the ASCO/CAP HER2 Guideline criteria.
 2. Evaluate and integrate HER2 test results with clinical and morphologic
     findings.
 3. Determine appropriate next steps when a HER2 test result is discordant
     with the patient's profile or other HER2 tests.
     compliance with regulatory requirements.
 4. Apply the ASCO/CAP Guideline criteria for reporting HER2 test results.
 5. Provide appropriate resolution and clarification in reports when HER2
     results are equivocal, indeterminate, or complex (eg, intratumoral
     heterogeneity or chromosome 17 aneusomy).


Dr. M. Elizabeth Hammond, MD, FCAP
Dr. David Hicks, MD, FCAP

Not being aware of your responsibilities as a pathologist using protected electronic health information can lead to the inadvertent disclosure of that information. Further, if your institution's systems and policies are not compliant with federal legislation and regulations, then it may be as risk for penalties. This interactive, CME webinar will address security and privacy requirements for managing patient data, as well as important compliance considerations.

Objectives:
 • Identify federal legislation relevant to patient data storage,
    access control, and transmission.
 • Discuss options for secure storage and transport of information.
 • Describe laboratory policies for personnel to use data and maintain
    compliance with regulatory requirements.


Dr. Myra Wilkerson, MD, FCAP

The pathologist has an important and burgeoning role in helping to order the right genomic test that will inform diagnostic, prognostic, and/or therapeutic decision-making. This interactive, CME webinar will address genomic test selection and interpretation, as well as how to educate and guide others as a molecular consultant. In addition, the webinar will prepare you to contribute and apply cancer genomic information in new ways to add value to the healthcare system.

Objectives:

 1. Identify criteria for selecting high-value molecular tests.
 2. Guide appropriate molecular test utilization.
 3. Interpret the diagnostic, prognostic, and therapeutic significance of
    genomic test results.
 4. Identify opportunities to educate healthcare providers on the
    significance and value of genomic testing.

Dr. Pranil Chandra, DO, FCAP

As the complexity of the data used to manage patients with chronic diseases such as cancer has grown, the task of the clinician has become increasingly difficult and time consuming. At worst, patient safety can be compromised or delivery of care delayed due to the difficulty in retrieving all of the necessary data elements needed for treatment. The need to retrieve test results from different departmental information systems such as the laboratory information system (LIS), the radiology picture archiving and communication system (PACS), different areas of the electronic medical record (EMR), and from systems external to the treating facility or hospital system, contribute to this situation. We outline a framework that takes advantages of the capabilities of electronic reporting to create an Integrated Disease Report (IDR) - a single, succinct, integrated, interpretive report comprising all data pertinent to the disease: pathology results, laboratory data, imaging correlations, risk profiles, and therapeutic implications. This is a free, non-CME webinar.

Monica E. de Baca, MD, FCAP
Director of Hematopathology, Hematologics Inc.
CAP Diagnostic Intelligence and Health IT (DIHIT) Committee member
Co-chair for the DIHIT Integrated Reporting Workgroup

George Birdsong, MD, FCAP
Department of Pathology and Laboratory Medicine
Emory University School of Medicine/Grady Health System, Atlanta, GA
CAP Diagnostic Intelligence and Health IT (DIHIT) Committee member
Co-chair for the DIHIT Integrated Reporting Workgroup

Monitoring key metrics informs a practice leader where their practice is performing well and where resources may be needed to improve the practice. This webinar reviews high-level metrics for monitoring a practice and examples of how to drill down to solve an identified improvement area. Stop flying blind and see what metrics others have found useful in demonstrating their value while improving patient care as well as their bottom line.

In vivo microscopy (IVM) involves imaging tissue microstructure from living patients. Potential applications of IVM include obtaining microscopic information from areas that are hazardous to sample (eye, brain, coronary arteries) and guiding biopsy sites so that the sampled tissue is more representative of the patient's true disease state. The focus on this webinar is on the applications of IVM focused on GI such as Barretts.

Since pathologists are expert at interpreting microscopic images, it is important that pathology as a field play a role in how these technologies will be used in medicine in the future. There are reimbursement and payment codes in place.
Learning objectives:
    •  Describe examples of IVM advanced imaging that offers new roles for
        pathologists.
    •  Explain the use of IVM for Barretts screening, selection of biopsy.
    •  Review implications to workflow


Presenter: Gregory Y. Lauwers, MD, FCAP

Esophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer death in the world. Most cases occur in developing countries, in geographic bands across Central Asia and from East to South Africa. The 5-year survival of ESCC is these high-risk areas is less than 5%, because symptoms occur late and patients present with unresectable tumors. In an effort to reduce ESCC mortality, an endoscopic screening and treatment program has been developed in China to evaluate high-risk asymptomatic adults for high-grade esophageal squamous dysplasia (ESD), the clinical precursor of ESCC, and this program now screens 200,000 people each year. Attempts have been made to use similar screening methods in Africa as well, but these efforts have been limited by a lack of pathology infrastructure. Most hospitals have no pathologist, and sending out a single biopsy often costs more than the endoscopy exam and requires waiting 2-4 weeks for a result.

Recently, high-resolution microendoscopy (HRME), a low-cost battery-operated probe-based imaging technique that provides subcellular 1100x epithelial images when used with a topical fluorescent contrast dye, has been evaluated for its ability to distinguish high-grade ESD from other mucosal histologies in vivo, with the hope that it can minimize the number of biopsies needed to correctly evaluate participants in such ESCC screening programs.

In this webinar, I will describe the Chinese endoscopic screening program for ESCC and a preliminary evaluation of HRME as an adjunct technology to make similar screening programs more practical in high-risk populations in Africa.

Learning objectives:
    •  Describe the endoscopic screening and treatment program
        or ESCC that is currently used in China
    •  Explain the basics of HRME imaging
    •  Describe how HRME imaging can potentially assist the
        implementation of ESCC screening in high-risk,
        low-resource populations in Africa


Presenter: Sandy Dawsey, MD